MFMatthew H. Forsberg

Matthew H. Forsberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew H. Forsberg has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Label-free metabolic imaging monitors the fitness of chimeric antigen receptor T cells

    by Dan L. Pham, Dan Cappabianca, Matthew H. Forsberg, Cole Weaver, Katherine P. Mueller, Anna Tommasi, Jolanta Vidugiriene, Anthony Lauer, Kayla Sylvester, Jorgo Lika, et al.

    Chimeric antigen receptor (CAR) T cell therapy for solid tumours is challenging because of the immunosuppressive tumour microenvironment and a complex manufacturing process. Cellular manufacturing protocols directly impact CAR T cell yield, phenotype and metabolism, which correlates with in vivo potency and persistence. Although metabolic fitness is a critical quality attribute, how T cell metabolic requirements vary throughout the manufacturing process remains unexplored. Here we use optical metabolic imaging (OMI), a non-invasive, label-free method to evaluate single-cell metabolism. Using OMI, we identified the impacts of media composition on CAR T cell metabolism, activation strength and kinetics, and phenotype. We demonstrate that OMI parameters can indicate cell cycle stage and optimal gene transfer conditions for both viral transduction and electroporation-based CRISPR/Cas9. In a CRISPR-edited anti-GD2 CAR T cell model, OMI measurements allow accurate prediction of an oxidative metabolic phenotype that yields higher in vivo potency against neuroblastoma. Our data support OMI as a robust, sensitive analytical tool to optimize manufacturing conditions and monitor cell metabolism for increased CAR T cell yield and metabolic fitness.


  • Open Access

    Low-dose radiation by radiopharmaceutical therapy enhances GD2 TRAC -CAR T cell efficacy in localized neuroblastoma

    by Quaovi H. Sodji, Amanda Shea, Dan Cappabianca, Matthew H. Forsberg, Jens C. Eickhoff, Malick Bio Idrissou, Andy S. Ollendorff, Ohyun Kwon, Irene M. Ong, Reinier Hernandez, et al.

    Chimeric antigen receptor (CAR) T cells have limited efficacy against solid tumors including neuroblastoma. Here, we evaluated whether low-dose radiation delivered by radiopharmaceutical therapy (RPT), known to potentiate immune checkpoint inhibitors, can synergize with CRISPR-edited GD2 TRAC- CAR T cells to improve outcomes in neuroblastoma. We found that in the localized model of neuroblastoma, low-dose radiation delivered by 177 Lu-NM600, an alkylphosphocholine mimetic RPT agent, followed 9 days later by GD2 TRAC- CAR T cells led to complete tumor regression. Irradiation of neuroblastoma before GD2 TRAC- CAR T cells enhanced the release by CAR T cells of perforin, granzyme B, tumor necrosis factor–α, and interleukin-7 while abrogating transforming growth factor–β1. Low-dose RPT up-regulated the death receptor Fas on neuroblastoma, potentially enabling CAR-independent killing. This suggests that low-dose RPT can enhance suboptimal CAR T cell efficacy against solid tumors. However, optimization of radiation dose and timing may be needed for each patient and RPT agent to account for varied tumor radiosensitivity and dosimetry.


  • Open Access

    Detection and viability of murine NK cells in vivo in a lymphoma model using fluorine‐19 MRI

    by Lawrence M. Lechuga, Matthew H. Forsberg, Kirsti L. Walker, Kai D. Ludwig, Christian M. Capitini, Sean B. Fain

    Natural killer (NK) cell therapies are being increasingly used as an adoptive cell therapy for cancer because they can recognize tumor cells in an antigen‐independent manner. While promising, the understanding of NK cell persistence, particularly within a harsh tumor microenvironment, is limited. Fluorine‐19 (19F) MRI is a noninvasive imaging modality that has shown promise in longitudinally tracking cell populations in vivo; however, it has not been studied on murine NK cells. In this study, the impact of 19F labeling on murine NK cell viability and function was assessed in vitro and then used to quantify NK cell persistence in vivo. While there was no noticeable impact on viability, labeling NK cells with 19F did attenuate cytotoxicity against lymphoma cells in vitro. Fluorescent microscopy verified 19F labeling in both the cytoplasm and nucleus of NK cells. Lymphoma‐bearing mice were given intratumoral injections of 19F‐labeled NK cells in which signal was detectable across the 6 day observation period via 19F MRI. Quantification from the composite images detected 78‐94% of the initially injected NK cells across 6 days, with a significant decrease between Days 3 and 6. Postmortem flow cytometry demonstrated retention of 19F intracellularly within adoptively transferred NK cells with less than 1% of 19F‐containing cells identified as tumor‐associated macrophages that presumably ingested nonviable NK cells. This work demonstrates that 19F MRI offers a specific imaging platform to track and quantify murine NK cells within tumors noninvasively.


  • Open Access

    Macrophages Educated with Exosomes from Primed Mesenchymal Stem Cells Treat Acute Radiation Syndrome by Promoting Hematopoietic Recovery

    by John A. Kink, Matthew H. Forsberg, Sofiya Reshetylo, Soroush Besharat, Charlie J. Childs, Jessica D. Pederson, Annette Gendron-Fitzpatrick, Melissa Graham, Paul D. Bates, Eric G. Schmuck, et al.


  • Open Access

    Combined congenic mapping and nuclease-based gene targeting for studying allele-specific effects of Tnfrsf9 within the Idd9.3 autoimmune diabetes locus

    by Matthew H. Forsberg, Bardees Foda, David V. Serreze, Yi-Guang Chen

    Rodent complex trait genetic studies involving a cross between two inbred strains are usually followed by congenic mapping to refine the loci responsible for the phenotype. However, progressing from a chromosomal region to the actual causal gene remains challenging because multiple polymorphic genes are often closely linked. The goal of this study was to develop a strategy that allows candidate gene testing by allele-specific expression without prior knowledge of the credible causal variant.Tnfrsf9(encoding CD137) is a candidate gene for theIdd9.3type 1 diabetes (T1D) susceptibility locus in the nonobese diabetic (NOD) mouse model. A C57BL/10Sn (B10)-derived diabetes resistanceIdd9.3congenic region has been shown to enhance accumulation of CD137+regulatory T cells and serum soluble CD137 in NOD mice. By combining the power of congenic mapping and nuclease-based gene targeting, we established a system where a pair of F1 hybrids expressed either the B10 or NODTnfrsf9allele mimicking coisogenic strains. Using this approach, we demonstrated that the allelic difference in B10 and NODTnfrsf9alone was sufficient to cause differential accumulation of CD137+regulatory T cells and serum soluble CD137 levels. This strategy can be broadly applied to other rodent genetic mapping studies.


  • Open Access

    The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL

    by Matthew H Forsberg, Amritava Das, Krishanu Saha, Christian M Capitini

    Recent advancements in immuno-oncology have resulted in the generation of novel therapies such as chimeric antigen receptor (CAR) T cells, which have revolutionized the treatment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The journey of tisagenlecleucel (formerly CTL019) from early preclinical success to the US Food and Drug Administration approval is summarized in this review. Strategies that are currently being investigated to improve the efficacy and safety profile of CAR T-cells are also explored, as well as the factors contributing to the present state of patient access to CAR T therapy.


  • Open Access

    CD137 Plays Both Pathogenic and Protective Roles in Type 1 Diabetes Development in NOD Mice

    by Matthew H. Forsberg, Ashley E Ciecko, Kyle J. Bednar, Arata Itoh, Kritika Kachapati, William M. Ridgway, Yi-Guang Chen

    We previously reported that CD137 (encoded by Tnfrsf9) deficiency suppressed type 1 diabetes (T1D) progression in NOD mice. We also demonstrated that soluble CD137 produced by regulatory T cells contributed to their autoimmune-suppressive function in this model. These results suggest that CD137 can either promote or suppress T1D development in NOD mice depending on where it is expressed. In this study, we show that NOD.Tnfrsf9−/− CD8 T cells had significantly reduced diabetogenic capacity, whereas absence of CD137 in non-T and non-B cells had a limited impact on T1D progression. In contrast, NOD.Tnfrsf9−/− CD4 T cells highly promoted T1D development. We further demonstrated that CD137 was important for the accumulation of β cell–autoreactive CD8 T cells but was dispensable for their activation in pancreatic lymph nodes. The frequency of islet-infiltrating CD8 T cells was reduced in NOD.Tnfrsf9−/− mice in part because of their decreased proliferation. Furthermore, CD137 deficiency did not suppress T1D development in NOD mice expressing the transgenic NY8.3 CD8 TCR. This suggests that increased precursor frequency of β cell–autoreactive CD8 T cells in NY8.3 mice obviated a role for CD137 in diabetogenesis. Finally, blocking CD137–CD137 ligand interaction significantly delayed T1D onset in NOD mice. Collectively, our results indicate that one important diabetogenic function of CD137 is to promote the expansion and accumulation of β cell–autoreactive CD8 T cells, and in the absence of CD137 or its interaction with CD137 ligand, T1D progression is suppressed.


  • Open Access

    Gene Targeting in NOD Mouse Embryos Using Zinc-Finger Nucleases

    by Yi-Guang Chen, Matthew H. Forsberg, Shamim Khaja, Ashley E. Ciecko, Martin J. Hessner, Aron M. Geurts

    Studies in NOD mice have provided important insight into the genetics and pathogenesis of type 1 diabetes (T1D). Our goal was to further explore novel methods of genetic manipulation in this mouse model. We tested the feasibility of using zinc-finger nucleases (ZFNs) to knock out a gene directly in a pure NOD background, bypassing the need of embryonic stem cells. We report here the successful application of ZFN pairs to specifically and efficiently knock out Tnfrsf9 (encoding CD137/4–1BB) directly in the NOD mouse by embryo microinjection. Histology and T1D incidence studies indicated that CD137 was dispensable for the development of insulitis but played a role to promote progression to overt diabetes in NOD mice. We also demonstrated that CD137-deficient T-cells were less diabetogenic than their wild-type counterpart when adoptively transferred into NOD.Rag1−/− recipients, even when CD25+ cells were predepleted. In vitro assays suggested that CD137 deficiency had a limited effect on the suppressive function of CD4+CD25+ regulatory T-cells (Tregs). Therefore, CD137 deficiency predominately affected effector T-cells rather than Tregs. Our study demonstrates the ability to generate gene-targeted knockouts in a pure NOD background by using ZFNs without potential confounding factors introduced by contaminating genetic materials obtained from other strains.